术后早期NSCLC辅助化疗期间分期中药治疗的患者报告结局:随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验纳入180例IB-IIIA期术后NSCLC患者,比较化疗联合分期中药与化疗联合安慰剂对患者报告结局的影响。结果显示,化疗联合中药组在18周时EORTC QLQ-C30总体健康状况/生活质量评分较基线改善,而安慰剂组下降,组间差异有统计学意义;中药组至恶化时间更长,不良事件发生率两组相近。
要点
- 术后早期NSCLC辅助化疗期间联合分期中药可改善患者报告的生活质量。
- 中药组总体健康状况/生活质量评分至恶化时间较安慰剂组延长。
- 中药组不良事件发生率未高于安慰剂组。
核心结论
- 分期中药治疗有助于改善术后早期NSCLC患者辅助化疗期间的患者报告结局,值得进一步临床研究。
研究设计与样本
- 前瞻性、双盲、随机、安慰剂对照试验,2017年12月14日至2020年8月28日纳入上海5家医院的180例IB-IIIA期NSCLC术后患者。
- 采用分层区组随机分为化疗联合中药组120例和化疗联合安慰剂组60例,最终173例纳入患者报告结局分析(中药组116例,安慰剂组57例)。
主要发现
- 基线EORTC QLQ-C30总体健康状况/生活质量评分两组分别为57.16±1.64和57.67±2.25(P>0.05)。
- 第18周时中药组总体健康状况/生活质量评分较基线改善,最小二乘均值变化为17.83(95%CI 14.29至21.38),安慰剂组下降,最小二乘均值变化为-13.67(95%CI -22.70至-4.63)。
- 两组最小二乘均值评分组间差异为31.63分(95%CI 25.61至37.64,P<0.001),体力功能、疲乏和食欲减退也呈现相似趋势。
- 第18周时中药组总体健康状况/生活质量功能与症状评分改善或稳定的患者比例高于安慰剂组(P<0.001)。
- 中药组总体健康状况/生活质量评分至恶化时间更长(HR=0.33,95%CI 0.23至0.48,P<0.0010),体力功能(HR=0.43,95%CI 0.25至0.75,P=0.0005)、疲乏(HR=0.47,95%CI 0.30至0.72,P<0.0001)和食欲减退(HR=0.65,95%CI 0.42至1.00,P=0.0215)也显示更长至恶化时间。
临床怎么用
- 对于术后IB-IIIA期NSCLC接受辅助化疗的患者,可考虑联合分期中药治疗以改善生活质量相关患者报告结局。
- 治疗期间需关注疲乏、食欲减退和体力功能等患者报告的症状与功能变化。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether the combination of chemotherapy with staged Chinese herbal medicine (CHM) therapy could enhance health-related quality of life (QoL) in non-small-cell lung cancer (NSCLC) patients and prolong the time before deterioration of lung cancer symptoms, in comparison to chemotherapy alone. METHODS: A prospective, double-blind, randomized, controlled trial was conducted from December 14, 2017 to August 28, 2020. A total of 180 patients with stage I B-IIIA NSCLC from 5 hospitals in Shanghai were randomly divided into chemotherapy combined with CHM (chemo+CHM) group (120 cases) or chemotherapy combined with placebo (chemo+placebo) group (60 cases) using stratified blocking randomization. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life-Core 30 Scale (QLQ-C30) was used to evaluate the patient-reported outcomes (PROs) during postoperative adjuvant chemotherapy in patients with early-stage NSCLC. Adverse events (AEs) were assessed in the safety analysis. RESULTS: Out of the total 180 patients, 173 patients (116 in the chemo+CHM group and 57 in the chemo+placebo group) were included in the PRO analyses. The initial mean QLQ-C30 Global Health Status (GHS)/QoL scores at baseline were 57.16 ± 1.64 and 57.67 ± 2.25 for the two respective groups (P>0.05). Compared with baseline, the chemo+CHM group had an improvement in EORTC QLQ-C30 GHS/QoL score at week 18 [least squares mean (LSM) change 17.83, 95% confidence interval (CI) 14.29 to 21.38]. Conversely, the chemo+placebo group had a decrease in the score (LSM change -13.67, 95% CI -22.70 to -4.63). A significant between-group difference in the LSM GHS/QoL score was observed, amounting to 31.63 points (95% CI 25.61 to 37.64, P<0.001). The similar trends were observed in physical functioning, fatigue and appetite loss. At week 18, patients in the chemo+CHM group had a higher proportion of improvement or stabilization in GHS/QoL functional and symptom scores compared to chemo+placebo group (P<0.001). The median time to deterioration was longer in the chemo+CHM group for GHS/QoL score [hazard ratio (HR)=0.33, 95% CI 0.23 to 0.48, P<0.0010], physical functioning (HR=0.43, 95% CI 0.25 to 0.75, P=0.0005), fatigue (HR=0.47, 95% CI 0.30 to 0.72, P<0.0001) and appetite loss (HR=0.65, 95% CI 0.42 to 1.00, P=0.0215). The incidence of AEs was lower in the chemo+CHM group than in the chemo+placebo group (9.83% vs. 15.79%, P=0.52). CONCLUSION: The staged CHM therapy could help improve the PROs of postoperative patients with early-stage NSCLC during adjuvant chemotherapy, which is worthy of further clinical research. (Registry No. NCT03372694).
引用
- Zhang YL, Jiao LJ, Gong YB, et al. Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial. Chin J Integr Med. 2024. PMID: 39266862. doi:10.1007/s11655-024-4114-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。